Cas:18960-62-8 Anilin-<1-13C> manufacturer & supplier

Chemical Name:Anilin-<1-13C>

CAS.NO:18960-62-8

Synonyms:Aniline-1-13C;MFCD01075583;1-<13C>-Anilin

Molecular Formula:C₆H₇N

Molecular Weight:94.11910

HS Code:

Physical and Chemical Properties:

Melting point:-6ºC(lit.)

Boiling point:184ºC(lit.)

Density:1.033 g/mL at 25ºC

Index of Refraction:n20/D 1.586(lit.)

PSA:26.02000

Exact Mass:94.06120

LogP:1.85000

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 1547 6.1/PG 2

Packing Group:

Contact us for information like Aniline-1-13C chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,-Anilin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-&lt Use and application,1-&lt technical grade,usp/ep/jp grade.

Related News: With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near Anilin-<1-13C> manufacturer From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. Anilin-<1-13C> supplier Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData��s Company Financials database. Anilin-<1-13C> vendor From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. Anilin-<1-13C> factory From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.